NCT03945617 (OPTIMAX) is a NA clinical trial of Unified Treatment Protocol in Anxiety Disorders, sponsored by University of Zurich.

Who is sponsoring NCT03945617?

NCT03945617 is sponsored by University of Zurich.

What drugs are being tested in NCT03945617?

Interventions in NCT03945617: Unified Treatment Protocol.

What condition does NCT03945617 study?

NCT03945617 studies Anxiety Disorders.

Is NCT03945617 still recruiting?

NCT03945617 is currently status unknown. Last updated 10 May 2019.

Last reviewed 2019-05-10 · How we verify

NCT03945617: OPTIMAX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimizing Psychotherapy for Anxiety Disorders

Status unknown NA Last updated 10 May 2019

What this trial tests

NA trial testing Unified Treatment Protocol in Anxiety Disorders in 200 participants. Status unknown.

Timeline

1 January 2018

Primary endpoint
1 May 2022

31 December 2023

Quick facts

Lead sponsor	University of Zurich
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	200
Start date	1 January 2018
Primary completion	1 May 2022
Estimated completion	31 December 2023
Sites	1 location across Switzerland

Drugs / interventions tested

Unified Treatment Protocol

Conditions studied

Anxiety Disorders — all drugs for Anxiety Disorders →

Sponsor

University of Zurich

Who can join

Adults 18 to 65, any sex, with Anxiety Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Anxiety disorders are highly prevalent and are associated with a high burden of disease, costs and individual impairment worldwide. Psychotherapy, especially cognitive behavioral therapy (CBT), is the first line treatment for anxiety disorders. CBT is effective in modifying dysfunctional cognitions and reducing avoidance behavior, thus leading to a lasting reduction of symptoms. Even though CBT is generally effective, around 50% of patients do not benefit sufficiently from this treatment. The current study aims at optimizing the treatment of anxiety disorders by identifying predictors of treatment response. Multiple (neuro-)psychological, biological, genetic and behavioral variables will be combined into a comprehensive prediction model of treatment outcome. Knowledge on predictors can then be used to improve therapy on an individual patient level.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Optimizing Outcomes in Psychotherapy for Anxiety Disorders Using Smartphone-Based and Passive Sensing Features: Protocol for a Randomized Controlled Trial.
Müller-Bardorff M, Schulz A, Paersch C, Recher D, et al · · 2024 · cited 3× · PMID 38743473 · DOI 10.2196/42547
Optimizing Outcomes in Psychotherapy for Anxiety Disorders (OPTIMAX) Protocol– A Randomized Controlled Trial on Efficacy and Response Prediction in a Transdiagnostic Psychotherapy Treatment for Anxiety Disorders
Müller-Bardorff M, Schulz A, Paersch C, Recher D, et al · · 2022 · DOI 10.31234/osf.io/yezaj

Verify or expand the search:

Other recruiting trials for Anxiety Disorders

Currently open trials in the same condition.

NCT07340281 — Biomarkers for Exercise · NA · recruiting
NCT07432945 — In Vivo Exposure vs. Videochat-Based Vicarious Exposure · NA · recruiting
NCT07316374 — AI Chatbots for Anxiety Mental Health Literacy · NA · active not recruiting
NCT07123467 — Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder · Phase 3 · recruiting
NCT07174947 — SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depre · Phase 2 · recruiting

Other University of Zurich trials

Trials by the same sponsor.

NCT07485699 — Soy Processing and Food Allergy · NA · not yet recruiting
NCT07516912 — Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland · not yet recruiting
NCT07473115 — Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustm · not yet recruiting
NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
NCT06481982 — Value of Advanced MRI Techniques in the Assessment of Endometriosis · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03945617 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Zurich
Last refreshed: 10 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03945617.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing